These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28588015)

  • 21. Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis.
    Elsäßer J; Janssen MW; Becker F; Suttmann H; Schmitt K; Sester U; Stöckle M; Sester M
    PLoS One; 2013; 8(9):e69892. PubMed ID: 24039703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanism of action of intravesical BCG. Biological bases and clinical applicability.].
    Carballido JA; Rodríguez Monsalve M
    Arch Esp Urol; 2018 May; 71(4):358-375. PubMed ID: 29745925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
    Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
    Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.
    Biot C; Rentsch CA; Gsponer JR; Birkhäuser FD; Jusforgues-Saklani H; Lemaître F; Auriau C; Bachmann A; Bousso P; Demangel C; Peduto L; Thalmann GN; Albert ML
    Sci Transl Med; 2012 Jun; 4(137):137ra72. PubMed ID: 22674550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling.
    Antonelli AC; Binyamin A; Hohl TM; Glickman MS; Redelman-Sidi G
    Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18627-18637. PubMed ID: 32680964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients.
    Herr HW
    Eur Urol; 2013 May; 63(5):832-5. PubMed ID: 22921719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
    Wang Y; Yang M; Yu Q; Yu L; Shao S; Wang X
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):85-93. PubMed ID: 25231670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
    Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
    Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral PD1
    Basak D; Mondal S; Srivastava SK; Sarkar D; Sarkar I; Basu S; Bhoumik A; Chowdhury S; Pal DK; Chatterjee S
    Cells; 2023 Jul; 12(15):. PubMed ID: 37566017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
    Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
    J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
    Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
    J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity.
    Ponticiello A; Perna F; Maione S; Stradolini M; Testa G; Terrazzano G; Ruggiero G; Malerba M; Sanduzzi A
    Respir Med; 2004 Jun; 98(6):509-14. PubMed ID: 15191035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
    Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
    BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remodeling the bladder tumor immune microenvironment by mycobacterial species with changes in their cell envelope composition.
    Senserrich J; Guallar-Garrido S; Gomez-Mora E; Urrea V; Clotet B; Julián E; Cabrera C
    Front Immunol; 2022; 13():993401. PubMed ID: 36304456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.